Melinda J. Gooderham April 25, 2022
J Eur Acad Dermatol Venereol. 2022 Apr 24. Online ahead of print.  BACKGROUND: Once-daily abrocitinib treatment provided meaningful improvements in signs and symptoms of moderate-to-severe atopic dermatitis (AD) in randomized controlled studies.   OBJECTIVE: To evaluate proportions of patients with responses meeting higher threshold efficacy responses than commonly used efficacy endpoints and to determine if these responses were associated with quality of life (QoL) benefits.   METHODS: Data from a phase 2b (NCT02780167) and 2 phase 3 studies (NCT03349060/JADE MONO-1; NCT03575871/JADE MONO-2) in adult and adolescent patients (N = 942) with moderate-to-severe AD receiving once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo were pooled. Commonly used (Eczema Area and Severity Index [EASI]-75 and ≥4-point improvement in Pruritus Numerical Rating Scale [PP-NRS4]) and higher threshold efficacy endpoints (EASI-90 to <EASI-100, EASI-100 or PP-NRS0/1 response) were evaluated. Proportions of patients across Children's Dermatology Life Quality Index/ Dermatology Life Quality Index (CDLQI/DLQI) band descriptors who achieved various efficacy endpoints were analyzed.   RESULTS: More abrocitinib-treated patients achieved commonly used or higher threshold efficacy endpoints at week 12 versus placebo. More abrocitinib-treated patients who achieved higher threshold efficacy endpoints reported "no effect" of AD on QoL (by CDLQI/DLQI) at week 12 versus those who achieved commonly used but not higher threshold efficacy endpoints (PP-NRS0/1 vs. PP-NRS4 but not PP-NRS0/1 responders [200 mg: 66.3% vs. 17.5%; 100 mg: 62.1% vs. 20.0%]; EASI-100, EASI-90 to <EASI-100 vs. EASI-75 to <EASI-90 responders [200 mg: 67.6%, 48.9% vs. 28.8%; 100 mg: 63.2%, 48.1% vs. 36.7%]).   CONCLUSIONS: Substantial proportions of patients with moderate-to-severe AD receiving abrocitinib met higher threshold efficacy endpoints, and this was associated with meaningful additional QoL benefits compared with those who did not meet these higher efficacy thresholds. Not only do a substantial proportion of abrocitinib-treated patients achieve higher threshold efficacy endpoints, but they also do so in a similar timeframe as for more commonly used thresholds for efficacy endpoints.  PMID:35462428 | DOI:10.1111/jdv.18170

Full text access may require purchase from the publisher, or a login through your institution's library or computer network.